ライフサイエンスコーパス: fucoidan

1 evealing CLEC-2 as a physiological target of fucoidan.

2 ted polysaccharide showed characteristics of fucoidan.

3 luding f-Alb, maleylated bovine albumin, and fucoidan.

4 tes is inhibited in the presence of EDTA and fucoidan.

5 the presence of EDTA and the polysaccharide fucoidan.

6 oidan (Fysk) and those of previously studied fucoidans.

7 In particular, administration of 2 doses of fucoidan (25 mg/kg) over 6 hours produces profound mobil

8 gregation and Syk phosphorylation induced by fucoidan, a CLEC-2 agonist, were unaffected in RhoG-defi

9 Fucoidan, a known ligand of class A macrophage scavenger

10 Fucoidan, a multifunctional marine polymer, is normally

11 Fucoidan, a sulfated polysaccharide from Fucus vesiculos

12 AV513 is a select fucoidan, a sulfated polysaccharide of botanical origin.

13 Similarly, fucoidan, a sulfated polysaccharide that binds to L-sele

14 ulocyte colony-stimulating factor (G-CSF) or fucoidan administration.

15 itive reconstitution experiments reveal that fucoidan also elicits long-term (more than 6 months) rep

16 Fucoidan also interferes with leukocyte rolling by bindi

17 In addition, fucoidan and EDTA abrogate the enhancing effect of HBP o

18 Particular emphasis on the fucoidan and phlorotannin polymeric fractions is given,

19 tes such as sulfated Le(x), heparan sulfate, fucoidan, and carrageenan.

20 f soluble glycoconjugates, of which heparin, fucoidan, and dextran sulfate were the most effective.

21 h as different glycosaminoglycans, alginate, fucoidan, and glycans were profiled by this comprehensiv

22 ulfate 500K, dextran sulfate 5K, sulfatides, fucoidan, and heparin but not by chondroitin sulfate A.

23 sigargin and the scavenger receptor A ligand fucoidan, and restoring iPLA(2)betaexpression with recom

24 fated polysaccharides from brown algae - the fucoidans - are known to be a topic of numerous studies,

25 Thus, our data show fucoidan as a novel CLEC-2 receptor agonist that activat

26 ger receptor inhibitors, dextran sulfate and fucoidan, attenuated monocyte migration toward stressed

27 ay shows that CLEC18 preferentially binds to fucoidan, beta-glucans, and galactans.

28 RNA for macrophage scavenger receptor A, and fucoidan blocking of macrophage scavenger receptors inhi

29 sulfated polysaccharides dextran sulfate and fucoidan, but not others, reduce endothelial cell-surfac

30 ture of algae and facilitates the release of fucoidan by hot water extraction.

31 Furthermore, we demonstrate that fucoidan, by itself, stimulates TNF-alpha release from i

32 We find that dextran sulfate and fucoidan can bridge the extracellular domain of NRP1 to

33 The sulfated polysaccharide fucoidan can rapidly mobilize hematopoietic progenitor c

34 Fucoidan competes for binding with anti-Ly-49A antibodie

35 In addition, it binds the polysaccharide fucoidan, consistent with its C-type lectin homology and

36 The sulfated glycoconjugates heparin, fucoidan, dextran sulfate 5000, and dextran sulfate 500

37 In colony formation assay the fucoidans from different species of brown algae showed s

38 vidence for further exploring the use of the fucoidans from S. cichorioides, F. evanescens, and U. pi

39 ifferent than those of commercial food grade fucoidan (Fysk) and those of previously studied fucoidan

40 Fucoidan has been used to inhibit the binding of various

41 Fucoidan, heparin, or dextran sulfate, all of which are

42 Furthermore, the efficacy of fucoidan in hemophilia raises the possibility that decre

43 apidly and dramatically after treatment with fucoidan in monkeys and in mice, coinciding with decreas

44 We report on a role for selectins and fucoidan in progenitor mobilization.

45 c release, and we find that thapsigargin and fucoidan induce mitochondrial phospholipid loss and cyto

46 hibition of elastase activity did not impair fucoidan-induced mobilization.

47 is not required but confers an advantage for fucoidan-induced mobilization.

48 Fucoidan-induced platelet activation had a lag phase, wh

49 Fucoidan-induced platelet activation was completely abol

50 On the other hand, fucoidan-induced platelet activation was inhibited in pl

51 ffect on platelets and the receptor by which fucoidan induces cellular processes has not been elucida

52 In this study, we demonstrate that fucoidan induces platelet activation in a concentration-

53 Sulfated polysaccharides (e.g. heparin and fucoidan) inhibited binding of soluble DC-HIL-Fc and adh

54 Fucoidan is a sulphated polysaccharide that consists mai

55 Sulfation is critical as desulfated fucoidan is ineffective.

56 In this study the effect of fucoidans isolated from brown algae Saccharina cichorioi

57 e, evidence is provided that the addition of fucoidan or dextran sulfate to unfractionated plasma res

58 t treatment with the sulfated polysaccharide fucoidan or the structurally similar dextran sulfate inc

59 d by negatively charged molecules, including fucoidan, poly I, and polyvinyl sulfate.

60 l inhibitors of class A scavenger receptors (fucoidan, polyinosinic acid, and dextran sulfate) reveal

61 The algal fucoidans specifically and markedly suppressed the proli

62 the antioxidant butylated hydroxytoluene nor fucoidan, suggesting that lipid accumulation did not inv

63 haM-/- HPCs were preferentially mobilized by fucoidan, suggesting that the enhanced mobilization is c

64 trations of a highly charged polysaccharide, fucoidan, the microscale ordering of Fmoc-FRGDF peptide

65 enon we found that BM myeloid cells bound to fucoidan through the integrin alphaMbeta2 (macrophage an

66 and the binding was inhibited by heparin and fucoidan, thus supporting the hypothesis that P97 was ac

67 erpretation of results from studies that use fucoidan to "block" either scavenger receptors or L- or

68 Administration of fucoidan to mice reduces VEGF(165)-induced angiogenesis

69 ng of acetylated low density lipoprotein and fucoidan to MSR-A in human THP-1 macrophages triggered t

70 kin-8, MCP1, or MMP9 were also present after fucoidan treatment, studies in gene-ablated mice (GCSFR(

71 1 (SDF-1) were achieved in alphaM-/- mice by fucoidan treatment.

72 Mobilization of HPCs by fucoidan was enhanced in animals deficient in alphaM (al

73 In this study, fucoidan was extracted from Sargassum binderi (Fsar) fro

74 in FcRgamma-chain null mice, indicating that fucoidan was not acting primarily through GPVI receptor.

75 Platelet activation by fucoidan was only slightly inhibited in FcRgamma-chain n

76 um and Saccorhiza polyschides, alginates and fucoidans were the main polysaccharides found.

77 oitin sulfates B and C, heparan sulfate, and fucoidan) were ineffective.

78 utination activity (i.e. dextran sulfate and fucoidan) whereas high concentrations inhibited parasite

79 reated with anti-P-selectin antibody or with fucoidan (which inhibits P- and L-selectin function).

80 Dextran sulfate and fucoidan, whose structures are widely divergent from hep

81 that Fsar has fundamental characteristics of fucoidan with different structural conformation i.e. var